Study of the ηπo\eta\pi^o system in the mass range up to 1200 MeV

The reaction $\pi^-p \to \eta\pi^o n$ has been studied with GAMS-2000 spectrometer in the secondary 38 GeV/c $\pi^-$-beam of the IHEP U-70 accelerator. Partial wave analysis of the reaction has been performed in the $\eta\pi^o$ mass range up to 1200 MeV. The $a_0(980)$-meson is seen as a sharp peak in S-wave. The $t$-dependence of $a_0(980)$ production cross section has been studied. Dominant production of the $a_0(980)$ at a small transfer momentum $t$ confirms the hypothesis of Achasov and Shestakov about significant contribution of the $\rho_2$ exchange ($I^GJ^{PC}=1^+2^{--}$) in the mechanism of $a_0(980)$ meson production in $t$-channel of the reaction.Comment: 4 pages, 3 figures, talk given at HADRON'9

A study of the f0(1370),f0(1500),f0(2000)f_{0}(1370), f_{0}(1500), f_{0}(2000) and f2(1950)f_{2}(1950) observed in centrally produced 4π\pi final states

The production and decay properties of the f0(1370), f0(1500), f0(2000) and f2(1950) have been studied in central pp interactions at 450 GeV/c. The dPT, phi and |t| distributions of these resonances are presented. For the J = 0 states, the f0(1370) and f0(2000) have similar dPT and phi dependences. These are different to the dPT and phi dependences of the f0(980), f0(1500) and f0(1710). For the J = 2 states the f2(1950) has different dependences to the f2(1270) and f2'(1520). This shows that the dPT and phi dependences are not just J phenome

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic <i>BRCA1/2</i> germline pathogenic variant carriers

Objective: The aim of this study was to describe the long-term outcome of asymptomatic BRCA1/2 germline pathogenic variant (GPV) carriers with high-grade serous carcinoma (HGSC) in their risk-reducing salpingo-oophorectomy (RRSO) specimen. Methods: In a previously described cohort of asymptomatic BRCA1/2 GPV carriers derived from the Hereditary Breast and Ovarian cancer in the Netherlands (HEBON) study, women with HGSC at RRSO were identified. Main outcome was ten-year disease-free survival (DFS). Secondary outcomes were time to recurrence, ten-year disease-specific survival (DSS), ten-year overall survival (OS). Patient, disease and treatment characteristics associated with recurrence were described. Results: The 28 included women with HGSC at RRSO were diagnosed at a median age of 55.3 years (range: 33.5–74.3). After staging, eighteen women had (FIGO) stage I, three stage II and five had stage III disease. Two women did not undergo surgical staging and were classified as unknown stage. After a median follow-up of 13.5 years (range: 9.1–24.7), six women with stage I (33%), one woman with stage II (33%), two women with stage III (40%) and none of the women with unknown stage developed a recurrence. Median time to recurrence was 6.9 years (range: 0.8–9.2 years). Ten-year DFS was 68%, ten-year DSS was 88% and ten-year OS was 82%. Conclusion: Most asymptomatic BRCA1/2 GPV carriers with HGSC at RRSO were diagnosed at an early stage. Nevertheless, after a median follow-up of 13.5 years, nine of the 28 women with HGSC at RRSO developed a recurrence after a median of 6.9 years.</p

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic <i>BRCA1/2</i> germline pathogenic variant carriers

Objective: The aim of this study was to describe the long-term outcome of asymptomatic BRCA1/2 germline pathogenic variant (GPV) carriers with high-grade serous carcinoma (HGSC) in their risk-reducing salpingo-oophorectomy (RRSO) specimen. Methods: In a previously described cohort of asymptomatic BRCA1/2 GPV carriers derived from the Hereditary Breast and Ovarian cancer in the Netherlands (HEBON) study, women with HGSC at RRSO were identified. Main outcome was ten-year disease-free survival (DFS). Secondary outcomes were time to recurrence, ten-year disease-specific survival (DSS), ten-year overall survival (OS). Patient, disease and treatment characteristics associated with recurrence were described. Results: The 28 included women with HGSC at RRSO were diagnosed at a median age of 55.3 years (range: 33.5–74.3). After staging, eighteen women had (FIGO) stage I, three stage II and five had stage III disease. Two women did not undergo surgical staging and were classified as unknown stage. After a median follow-up of 13.5 years (range: 9.1–24.7), six women with stage I (33%), one woman with stage II (33%), two women with stage III (40%) and none of the women with unknown stage developed a recurrence. Median time to recurrence was 6.9 years (range: 0.8–9.2 years). Ten-year DFS was 68%, ten-year DSS was 88% and ten-year OS was 82%. Conclusion: Most asymptomatic BRCA1/2 GPV carriers with HGSC at RRSO were diagnosed at an early stage. Nevertheless, after a median follow-up of 13.5 years, nine of the 28 women with HGSC at RRSO developed a recurrence after a median of 6.9 years.</p

A partial wave analysis of the centrally produced K+K−K^{+}K^{-} and Ks0Ks0K^{0}_{s}K^{0}_{s} systems in pp interactions at 450 GeV/c and new information on the spin of the f1f_{1} (1710)

A partial wave analysis of the centrally produced K+K- and K0K0 channels has been performed in pp collisions using an incident beam momentum of 450 GeV/c. An unambiguous physical solution has been found in each channel. The striking feature is the observation of peaks in the S-wave corresponding to the f0(1500) and fJ(1710) with J = 0. The D-wave shows evidence for the f2(1270)/a2(1320), the f2(1525) and the f2(2150) but there is no evidence for a statistically significant contribution in the D-wave in the 1.7 GeV mass region

A kinematical selection of glueball candidates in central production

A study of central meson production as a function of the difference in transverse momentum ($dP_T$) of the exchanged particles shows that undisputed $q \overline q$ mesons are suppressed at small $dP_T$ whereas the glueball candidates are enhanced